This report assesses how pharmaceutical pricing and reimbursement policies have contributed to the achievement of certain health policy objectives, and it examines the national and transnational effects of these policies.Since May 2002, the NHS has paid for four multiple sclerosis products (Avonex, Betaferon, Copaxone and Rebif) under a ... diseases without using excessive resources, or protecting the health service from paying when the drug did not work. ... and payers in OECD countries use other techniques to limit the prices or set the reimbursement prices of pharmaceuticals. ... proposed by the manufacturer without negotiation (i.e., the social insurance scheme acts as a passive price-taker).
|Title||:||OECD Health Policy Studies Pharmaceutical Pricing Policies in a Global Market|
|Publisher||:||OECD Publishing - 2008-09-24|